Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Currency
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verastem (GB:0LOV)
LSE:0LOV
Verastem (0LOV) Share Price & Analysis
2 Followers
0LOV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.44 - $15.12
Previous Close$7.43
Volume4.00
Average Volume (3M)315.00
Market Cap
$185.97M
Enterprise Value$62.34M
Total Cash (Recent Filing)$165.66M
Total Debt (Recent Filing)$42.04M
Price to Earnings (P/E)N/A
Beta0.88
Next Earnings
Mar 12, 2024EPS Estimate
-$0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding25,267,436
10 Day Avg. Volume2,798
30 Day Avg. Volume315
Standard Deviation0.23
R-Squared0.05
Alpha0.00588
Financial Highlights & Ratios
Price to Book (P/B)2.24
Price to Sales (P/S)49.43
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit24.01
Enterprise Value/Ebitda-1.15
Forecast
1Y Price Target
$27.92Price Target Upside275.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Verastem News
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
52.71% Other Institutional Investors
47.29% Public Companies and
Individual Investors
0LOV FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest share price was $4.44 and its highest was $15.12 in the past 12 months.
What is Verastem’s market cap?
Currently, no data Available
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Mar 12, 2024 which is in 92 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Nov 08, 2023. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.843 by $0.093.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -$0.64.
How many shares outstanding does Verastem have?
Currently, no data Available
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.843. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Verastem?
Among the largest hedge funds holding Verastem’s share is Viking Global Investors LP. It holds Verastem’s shares valued at 20M.
---
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.92 (275.77% Upside)
$27.92 (275.77% Upside)
Blogger Sentiment
Bullish
GB:0LOV Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $18.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
49.68%
12-Months-Change
Fundamentals
Return on Equity
-91.87%
Trailing 12-Months
Asset Growth
58.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Verastem
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
---
---